Sarah M. Cohen
Patent Agent
Dr. Sarah M. Cohen is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her background includes extensive knowledge in genetics, chemical biology, molecular biology, metabolomics, and analytical chemistry. Sarah applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.
Prior to joining the firm, Sarah completed her doctorate degree at the California Institute of Technology under the supervision of Professor Paul W. Sternberg. Her dissertation focused on the formation and function of small molecules in nematode worms.
Experience
Dr. Sarah M. Cohen is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her background includes extensive knowledge in genetics, chemical biology, molecular biology, metabolomics, and analytical chemistry. Sarah applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.
Prior to joining the firm, Sarah completed her doctorate degree at the California Institute of Technology under the supervision of Professor Paul W. Sternberg. Her dissertation focused on the formation and function of small molecules in nematode worms.
Education
- Ph.D., Biology, California Institute of Technology, 2021NSF GRFP Fellow
- B.S., Double Major in Chemistry and Government, Cornell University, 2015
Magna Cum Laude; Science Editor, Cornell Daily Sun
Admissions
- U.S. Patent and Trademark Office
Credentials
Education
- Ph.D., Biology, California Institute of Technology, 2021NSF GRFP Fellow
- B.S., Double Major in Chemistry and Government, Cornell University, 2015
Magna Cum Laude; Science Editor, Cornell Daily Sun
Admissions
- U.S. Patent and Trademark Office
Select Publications
- Co-author with C.J.J. Wrobel, S.J. Prakash, F.C. Shroeder, and P.W. Sternberg, "Formation and function of dauer ascarosides in the nematodes Caenorhabditis briggsae and Caenorhabditis elegans," 12(3) G3 Genes|Genomes|Genetics, March 2022
- Co-author with C.M. Chai, W. Chen, W.R. Wong, H. Park, X. Wan, and P.W. Sternberg, "A Conserved Behavioral Role for a Nematode Interneuron Neuropeptide Receptor," Genetics, January 4, 2022
- Co-author with C.J.J. Wrobel, J. Yu, P.R. Rodrigues, A.H. Ludewig, B.J. Curtis, B.W. Fox, M.P. O’Donnell, P.W. Sternberg, and F.C. Schroeder, “Combinatorial Assembly of Modular Glucosides via Carboxylesterases Regulates C. elegans Starvation Survival,” J Am Chem Soc., August 30, 2021
- Co-author with H.H. Le, and P.W. Sternberg, “A Mutation of lips-6 in C. elegans,” MicroPubl Biol., July 9, 2021
- Co-author with J.J. Sun, F.C. Schroeder, and P.W. Sternberg, “Transcriptional Response to a Dauer-Inducing Ascaroside Cocktail in Late L1 in C. elegans,” MicroPubl Biol., May 12, 2021
- Co-author with H.H. Le, C.J. Wrobel, J. Yu, H. Park, M.J. Helf, B.J. Curtis, J.C. Kruempel, P.R. Rodrigues, P.J. Hu, P.W. Sternberg, and F.C. Schroeder, “Modular metabolite assembly in Caenorhabditis elegans depends on carboxylesterases and formation of lysosome-related organelles,” Elife, October 16, 2020
- Co-author with P. Sternberg, “Genome editing of Caenorhabditis briggsae using CRISPR/Cas9 co-conversion marker dpy-10,” MicroPubl Biol., October 11, 2019
- Co-author with H. Hosokawa, J. Ungerbäck, X. Wang, M. Matsumoto, K.I. Nakayama, T. Tanaka, and E.V. Rothenberg, “Transcription Factor PU.1 Represses and Activates Gene Expression in Early T Cells by Redirecting Partner Transcription Factor Binding,” Immunity, June 19, 2018
- Co-author with O. Panda, A.E. Akagi, A.B. Artyukhin, J.C. Judkins, H.H. Le, P. Mahanti, P.W. Sternberg, and F.C. Schroeder, “Biosynthesis of Modular Ascarosides in C. elegans,” Angew Chem Int Ed Engl., April 18, 2017
Insights
Select Publications
- Co-author with C.J.J. Wrobel, S.J. Prakash, F.C. Shroeder, and P.W. Sternberg, "Formation and function of dauer ascarosides in the nematodes Caenorhabditis briggsae and Caenorhabditis elegans," 12(3) G3 Genes|Genomes|Genetics, March 2022
- Co-author with C.M. Chai, W. Chen, W.R. Wong, H. Park, X. Wan, and P.W. Sternberg, "A Conserved Behavioral Role for a Nematode Interneuron Neuropeptide Receptor," Genetics, January 4, 2022
- Co-author with C.J.J. Wrobel, J. Yu, P.R. Rodrigues, A.H. Ludewig, B.J. Curtis, B.W. Fox, M.P. O’Donnell, P.W. Sternberg, and F.C. Schroeder, “Combinatorial Assembly of Modular Glucosides via Carboxylesterases Regulates C. elegans Starvation Survival,” J Am Chem Soc., August 30, 2021
- Co-author with H.H. Le, and P.W. Sternberg, “A Mutation of lips-6 in C. elegans,” MicroPubl Biol., July 9, 2021
- Co-author with J.J. Sun, F.C. Schroeder, and P.W. Sternberg, “Transcriptional Response to a Dauer-Inducing Ascaroside Cocktail in Late L1 in C. elegans,” MicroPubl Biol., May 12, 2021
- Co-author with H.H. Le, C.J. Wrobel, J. Yu, H. Park, M.J. Helf, B.J. Curtis, J.C. Kruempel, P.R. Rodrigues, P.J. Hu, P.W. Sternberg, and F.C. Schroeder, “Modular metabolite assembly in Caenorhabditis elegans depends on carboxylesterases and formation of lysosome-related organelles,” Elife, October 16, 2020
- Co-author with P. Sternberg, “Genome editing of Caenorhabditis briggsae using CRISPR/Cas9 co-conversion marker dpy-10,” MicroPubl Biol., October 11, 2019
- Co-author with H. Hosokawa, J. Ungerbäck, X. Wang, M. Matsumoto, K.I. Nakayama, T. Tanaka, and E.V. Rothenberg, “Transcription Factor PU.1 Represses and Activates Gene Expression in Early T Cells by Redirecting Partner Transcription Factor Binding,” Immunity, June 19, 2018
- Co-author with O. Panda, A.E. Akagi, A.B. Artyukhin, J.C. Judkins, H.H. Le, P. Mahanti, P.W. Sternberg, and F.C. Schroeder, “Biosynthesis of Modular Ascarosides in C. elegans,” Angew Chem Int Ed Engl., April 18, 2017
Biological Sciences and Biotechnology
- Antibody
- Biochemistry
- Cell biology
- Cellular biology
- Epigenetics
- Genetics
- Genomics
- Host-pathogen interactions
- Immunology
- Metabolomics
- Microbiology
- Molecular biology
- Molecular genetics
- PCR
Therapeutics and Drug Discovery
- CRISPR
- Gene editing
- Gene therapy
- Peptide therapeutics
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Chemistry
- Organic chemistry
Genomics and Data Analysis
- Next-generation sequencing
- Sequencing
Technical Fluency
Biological Sciences and Biotechnology
- Antibody
- Biochemistry
- Cell biology
- Cellular biology
- Epigenetics
- Genetics
- Genomics
- Host-pathogen interactions
- Immunology
- Metabolomics
- Microbiology
- Molecular biology
- Molecular genetics
- PCR
Therapeutics and Drug Discovery
- CRISPR
- Gene editing
- Gene therapy
- Peptide therapeutics
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Chemistry
- Organic chemistry
Genomics and Data Analysis
- Next-generation sequencing
- Sequencing
Recent Insights
Client Highlights
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
Learn More
Client Highlights
Firm Advises Predicta Biosciences on IP Matters Related to Oversubscribed $23.4 Million Series A
On October 1, 2025, Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, announced it has raised an oversubscribed $23.4 million Series A financing led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute, and Myeloma Solutions Fund. Wilson Sonsini Goodrich & Rosati advised Predicta on IP matters related to the transaction.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.